Artiva Biotherapeutics, Inc.
Income Statement
| Line Item | Jul 2026 | Jun 2026 | Apr 2026 | Mar 2026 | Feb 2026 | Oct 2025 | Sep 2025 | Jul 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $21.9M | — | $19.3M | — | — | $17.6M | — |
| SG&A Expense | — | $5.0M | — | $5.1M | — | — | $5.3M | — |
| Operating Income | — | $-26.9M | — | $-24.4M | — | — | $-22.9M | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | — | $-25.0M | — | $-23.5M | — | — | $-21.5M | — |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-0.63 | — | $-0.95 | — | — | $-0.44 | — |
| EPS (Diluted) | — | $-0.63 | — | $-0.95 | — | — | $-0.44 | — |
| Shares Outstanding (Basic) | 48.9M | 39.4M | 24.7M | 24.7M | 24.7M | 49.1M | 49.0M | 48.9M |
| Shares Outstanding (Diluted) | 48.9M | 39.4M | 24.7M | 24.7M | 24.7M | 49.1M | 49.0M | 48.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |